The whole body of evidence discussed in this article shows that brain dopamine can be
regarded as a strong candidate for a physiologically active substance, regulating the functioning …

The importance of the striatal dopamine (DA) deficiency and the DA substituting property of
levodopa for the pathophysiology and therapy of Parkinson's disease (PD) is reiterated. In …

Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD)
and the “gold standard” against which new agents must be compared. However, there …

A clinical, morphological and neurochemical correlative study in patients with Parkinson's
syndrome and Huntington's chorea is reported. In the former group of patients, 69 brains were …

Autografting of dopamine-producing adrenal medullary tissue to the striatal region of the
brain is now being attempted in patients with Parkinson's disease. Since the success of this …

Behavioural, histopathological and neurochemical changes induced by systemic injection
of kainic acid (10mg/kg, sc) were investigated in rats. The most pronounced behavioural …

Post-mortem brain material from control and Parkinson's disease patients was examined to
elucidate further the neurochemistry of this disease and to determine the mechanism of …

We report our experience with 15 patients believed to have cortical-basal ganglionic
degeneration. The clinical picture is distinctive, comprising features referable to both cortical and …

In this study, a comparative analysis of metal-related neuronal vulnerability was performed in
two brainstem nuclei, the locus coeruleus (LC) and substantia nigra (SN), known targets of …

IN patients with Parkinson's disease, the concentration of dopamine in the basal ganglia of
the brain is markedly reduced in accordance with the degeneration of the nigrostriatal …